US biotech firm enjoys Novo stock exchange effect after partnership announcement
Omega, which is developing technology for an epigenetic treatment for obesity, is booming on the New York Stock Exchange after signing a deal with Novo Nordisk.
af marketwire
The biotech company Omega Therapeutics, which is one of two companies that Novo Nordisk signed agreements with on Thursday in the areas of obesity and liver failure, is soaring on the New York Stock Exchange.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
